NO20083030L - 1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer - Google Patents

1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer

Info

Publication number: NO20083030L
Authority: NO; Norway
Prior art keywords: compounds; inhibitors; formula; treatment; insulin resistance
Prior art date: 2005-12-08

Application number

NO20083030A

Other languages

English (en)

Norwegian (no)

Inventor

Gary Mark Coppola

Travis Mathew Stams

Sidney Wolf Topiol

David Barnes

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-08

Filing date

2008-07-04

Publication date

2008-08-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37903424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083030(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-07-04 Application filed by Novartis Ag filed Critical Novartis Ag

2008-08-28 Publication of NO20083030L publication Critical patent/NO20083030L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Pulmonology (AREA)

NO20083030A 2005-12-08 2008-07-04 1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer NO20083030L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US74849205P	2005-12-08	2005-12-08
PCT/US2006/046542 WO2007067612A1 (en)	2005-12-08	2006-12-06	1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors

Publications (1)

Publication Number	Publication Date
NO20083030L true NO20083030L (no)	2008-08-28

Family

ID=37903424

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20083030A NO20083030L (no)	2005-12-08	2008-07-04	1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer

Country Status (23)

Country	Link
US (1)	US8252820B2 (es)
EP (1)	EP1963293A1 (es)
JP (1)	JP2009518419A (es)
KR (1)	KR20080075218A (es)
CN (1)	CN101336235A (es)
AR (1)	AR058285A1 (es)
AU (1)	AU2006321902B2 (es)
BR (1)	BRPI0619567A2 (es)
CA (1)	CA2631007A1 (es)
CR (1)	CR10047A (es)
EC (1)	ECSP088509A (es)
GT (1)	GT200800093A (es)
IL (1)	IL191711A0 (es)
MA (1)	MA30018B1 (es)
NO (1)	NO20083030L (es)
NZ (1)	NZ568663A (es)
PE (2)	PE20100470A1 (es)
RU (1)	RU2008127262A (es)
TN (1)	TNSN08248A1 (es)
TW (1)	TW200800928A (es)
UA (1)	UA94921C2 (es)
WO (1)	WO2007067612A1 (es)
ZA (1)	ZA200804489B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1963294B1 (en) *	2005-12-08	2012-10-10	Novartis AG	1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
KR20080074966A (ko) *	2005-12-08	2008-08-13	노파르티스 아게	1,1,3-트리옥소-1,2,5-티아디아졸리딘 및 ｐｔｐ-ａｓｅ억제제로서의 그의 용도
US8084448B2 (en)	2006-03-31	2011-12-27	Novartis Ag	Organic compounds
DE102007015169A1 (de) *	2007-03-27	2008-10-02	Universität des Saarlandes Campus Saarbrücken	17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2012027134A1 (en) *	2010-08-26	2012-03-01	Albemarle Corporation	Processes for producing 1-bromo-2 (cyclopropyl methoxy)-5 fluoro-4- methoxybenzene
US9040525B2 (en)	2010-10-08	2015-05-26	Mochida Pharmaceutical Co., Ltd.	Cyclic amide derivative
EP2683705B1 (de)	2011-03-08	2015-04-22	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de)	2011-03-08	2012-09-13	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012147516A1 (ja)	2011-04-28	2012-11-01	持田製薬株式会社	環状アミド誘導体
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2017078499A2 (ko) *	2015-11-06	2017-05-11	경북대학교 산학협력단	단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
UY38272A (es) *	2018-06-21	2019-12-31	Abbvie Inc	Inhibidores de proteína tirosina fosfatasa y sus métodos de uso
CR20210145A (es)	2018-09-18	2021-04-29	Basf Se	Compuestos de diaminotriazina
CA3131894A1 (en) *	2019-03-14	2020-09-17	Calico Life Sciences Llc	Protein tyrosine phosphatase inhibitors and methods of use thereof
CN116348455A (zh) *	2019-12-18	2023-06-27	卡里科生命科学有限责任公司	蛋白质酪氨酸磷酸酶抑制剂和其使用方法
JP2023508914A (ja) *	2019-12-20	2023-03-06	カリコライフサイエンシーズエルエルシー	プロテインチロシンホスファターゼ分解剤及びその使用方法
AU2021342161A1 (en) *	2020-09-11	2023-05-25	Abbvie Inc.	Protein tyrosine phosphatase inhibitors and methods of use thereof
CA3205911A1 (en)	2021-01-27	2022-08-04	Danny GEERDINK	Diaminotriazine compounds
AU2022234402A1 (en) *	2021-03-11	2023-09-28	Kumquat Biosciences Inc.	Heterocycles and uses thereof
EP4351558A4 (en) *	2021-06-10	2025-05-07	Ness Therapeutics, Inc.	Compounds containing 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes
EP4430038A1 (en) *	2021-11-11	2024-09-18	Calico Life Sciences LLC	Protein tyrosine phosphatase inhibitors and methods of use thereof
CA3236853A1 (en) *	2021-11-11	2023-05-19	Andrew Bogdan	Protein tyrosine phosphatase inhibitors and methods of use thereof
CN118660875A (zh) *	2022-01-31	2024-09-17	百时美施贵宝公司	蛋白酪氨酸磷酸酶抑制剂、组合物和使用方法
US20250136564A1 (en) *	2022-02-02	2025-05-01	Nerio Therapeutics, Inc.	Protein tyrosine phosphatase inhibitors and uses thereof
JP2025505994A (ja) *	2022-02-02	2025-03-05	ネリオセラピューティクス，インク．	プロテインチロシンホスファターゼ阻害剤およびその使用
IL314650A (en) *	2022-02-02	2024-09-01	Nerio Therapeutics Inc	Protein tyrosine phosphatase inhibitors and uses thereof
CN117658947A (zh) *	2022-09-06	2024-03-08	杭州中美华东制药有限公司	蛋白酪氨酸磷酸酶抑制作用的5-(取代芳基)-1,2,5-噻二唑啉-3-酮类化合物
JP2025530135A (ja) *	2022-09-13	2025-09-11	カムクワットバイオサイエンシーズインコーポレイテッド	ベンゾ縮合ｎ－複素環及びその使用
WO2024067802A1 (zh) *	2022-09-30	2024-04-04	深圳众格生物科技有限公司	蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
JP2025539027A (ja) *	2022-11-09	2025-12-03	ブリストル－マイヤーズスクイブカンパニー	タンパク質チロシンホスファターゼの阻害剤、組成物、および使用方法
AR131413A1 (es) *	2022-12-21	2025-03-19	Bristol Myers Squibb Co	Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
WO2024141015A1 (en) *	2022-12-30	2024-07-04	Insilico Medicine Ip Limited	Protein tyrosine phosphatase inhibitors and uses thereof
CN118852335A (zh) *	2023-04-28	2024-10-29	中科中山药物创新研究院	噻二唑烷酮衍生物及其制备方法和应用
WO2025011570A1 (zh) *	2023-07-11	2025-01-16	深圳众格生物科技有限公司	蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
TW202519514A (zh) *	2023-07-14	2025-05-16	天主教魯汶大學	新穎化合物(一)
TW202519218A (zh) *	2023-08-02	2025-05-16	美商耐瑞歐醫療公司	蛋白質酪胺酸磷酸酶抑制劑之組合
WO2025055985A1 (zh) *	2023-09-15	2025-03-20	深圳众格生物科技有限公司	蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
CN120004876A (zh) *	2023-11-16	2025-05-16	英矽智能科技(上海)有限公司	蛋白酪氨酸磷酸酶抑制剂及其应用
CN117343052B (zh) *	2023-12-04	2024-02-06	英矽智能科技(上海)有限公司	蛋白酪氨酸磷酸酶抑制剂及其应用
CN119707953A (zh) *	2024-04-19	2025-03-28	中国药科大学	噻二唑烷酮衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002076439A2 (en) *	2001-03-23	2002-10-03	The Board Of Trustees Of The University Of Illinois	Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
EP2341049A1 (en)	2002-04-03	2011-07-06	Novartis AG	5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors
GB0225986D0 (en) *	2002-11-07	2002-12-11	Astrazeneca Ab	Chemical compounds
GB0227813D0 (en) *	2002-11-29	2003-01-08	Astrazeneca Ab	Chemical compounds
DE60327811D1 (de) *	2002-12-30	2009-07-09	Vertex Pharma	Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen
US7135575B2 (en) *	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
WO2005035551A2 (en) *	2003-10-08	2005-04-21	Incyte Corporation	Inhibitors of proteins that bind phosphorylated molecules
KR20080074966A (ko)	2005-12-08	2008-08-13	노파르티스 아게	1,1,3-트리옥소-1,2,5-티아디아졸리딘 및 ｐｔｐ-ａｓｅ억제제로서의 그의 용도
EP1963294B1 (en)	2005-12-08	2012-10-10	Novartis AG	1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
UA94724C2 (en)	2005-12-08	2011-06-10	Новартис Аг	Thiadiazolidinone derivatives as antidiabetic agents
US8084448B2 (en)	2006-03-31	2011-12-27	Novartis Ag	Organic compounds

2006
- 2006-06-12 UA UAA200807752A patent/UA94921C2/ru unknown
- 2006-12-06 RU RU2008127262/04A patent/RU2008127262A/ru not_active Application Discontinuation
- 2006-12-06 KR KR1020087016433A patent/KR20080075218A/ko not_active Ceased
- 2006-12-06 WO PCT/US2006/046542 patent/WO2007067612A1/en not_active Ceased
- 2006-12-06 PE PE2010000301A patent/PE20100470A1/es not_active Application Discontinuation
- 2006-12-06 AR ARP060105391A patent/AR058285A1/es not_active Application Discontinuation
- 2006-12-06 BR BRPI0619567-9A patent/BRPI0619567A2/pt not_active IP Right Cessation
- 2006-12-06 CA CA002631007A patent/CA2631007A1/en not_active Abandoned
- 2006-12-06 US US12/096,432 patent/US8252820B2/en not_active Expired - Fee Related
- 2006-12-06 CN CNA2006800524439A patent/CN101336235A/zh active Pending
- 2006-12-06 PE PE2006001572A patent/PE20071094A1/es not_active Application Discontinuation
- 2006-12-06 AU AU2006321902A patent/AU2006321902B2/en not_active Ceased
- 2006-12-06 EP EP06844889A patent/EP1963293A1/en not_active Withdrawn
- 2006-12-06 JP JP2008544464A patent/JP2009518419A/ja active Pending
- 2006-12-06 NZ NZ568663A patent/NZ568663A/en not_active IP Right Cessation
- 2006-12-07 TW TW095145872A patent/TW200800928A/zh unknown
2008
- 2008-05-26 IL IL191711A patent/IL191711A0/en unknown
- 2008-05-27 ZA ZA200804489A patent/ZA200804489B/xx unknown
- 2008-06-02 MA MA30986A patent/MA30018B1/fr unknown
- 2008-06-05 CR CR10047A patent/CR10047A/es not_active Application Discontinuation
- 2008-06-06 GT GT200800093A patent/GT200800093A/es unknown
- 2008-06-06 TN TNP2008000248A patent/TNSN08248A1/en unknown
- 2008-06-06 EC EC2008008509A patent/ECSP088509A/es unknown
- 2008-07-04 NO NO20083030A patent/NO20083030L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN101336235A (zh)	2008-12-31
UA94921C2 (en)	2011-06-25
EP1963293A1 (en)	2008-09-03
ECSP088509A (es)	2008-07-30
GT200800093A (es)	2010-07-09
KR20080075218A (ko)	2008-08-14
MA30018B1 (fr)	2008-12-01
CR10047A (es)	2008-10-16
TNSN08248A1 (en)	2009-10-30
JP2009518419A (ja)	2009-05-07
AU2006321902B2 (en)	2011-11-10
US8252820B2 (en)	2012-08-28
WO2007067612A1 (en)	2007-06-14
NZ568663A (en)	2011-07-29
TW200800928A (en)	2008-01-01
IL191711A0 (en)	2008-12-29
AR058285A1 (es)	2008-01-30
PE20071094A1 (es)	2008-01-07
US20100035942A1 (en)	2010-02-11
RU2008127262A (ru)	2010-01-20
AU2006321902A1 (en)	2007-06-14
ZA200804489B (en)	2009-08-26
BRPI0619567A2 (pt)	2011-10-04
CA2631007A1 (en)	2007-06-14
PE20100470A1 (es)	2010-07-13

Publication	Publication Date	Title
NO20083030L (no)	2008-08-28	1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer
NO20083031L (no)	2008-08-28	Tiadiazolderivater som anti-diabetiske agenter
TNSN08247A1 (en)	2009-10-30	1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
WO2007115058A3 (en)	2008-03-20	Thiadiazolidinone inhibitors of ptpase
NO20044745L (no)	2004-12-14	5-substituerte 1,1-diokso-1,2,5-tiazolidin-3-on-derivater som PTPASE 1B inhibitorer
Cameron et al.	2016	Discovery and preclinical characterization of 6-chloro-5-[4-(1-hydroxycyclobutyl) phenyl]-1 H-indole-3-carboxylic acid (PF-06409577), a direct activator of adenosine monophosphate-activated protein kinase (AMPK), for the potential treatment of diabetic nephropathy
AR066820A1 (es)	2009-09-16	Compuestos de tiadiazolidin-3 ona
Liu et al.	2019	p53 modifications: exquisite decorations of the powerful guardian
Pellock et al.	2018	Gut microbial β-glucuronidase inhibition via catalytic cycle interception
GEP20135724B (en)	2013-01-10	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
NO20091700L (no)	2009-06-16	Florizinanaloger som inhibitorer av glukose-ko-transporter 2
WO2007070434A3 (en)	2008-03-06	Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
WO2007149451A3 (en)	2008-02-21	Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
WO2008033562A3 (en)	2008-08-21	Kinase inhibitor compounds
EP1796669A4 (en)	2009-08-19	AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
WO2006058064A3 (en)	2006-10-05	Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP1921917A4 (en)	2010-08-04	CONDENSED AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
EA200870380A1 (ru)	2009-02-27	Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
EA201270215A1 (ru)	2012-11-30	Apaf-1 ингибиторные соединения
NO20075731L (no)	2008-01-17	Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjon
Mellini et al.	2019	Identification of diketopiperazine-containing 2-anilinobenzamides as potent sirtuin 2 (SIRT2)-Selective inhibitors targeting the “selectivity pocket”, substrate-binding site, and NAD+-Binding site
WO2007136640A3 (en)	2008-04-10	Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
MX2007005590A (es)	2007-05-24	Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
Zhao et al.	2020	Post-translational modifications of nuclear sirtuins
Santin et al.	2013	Role of an indole-thiazolidine molecule PPAR pan-agonist and COX inhibitor on inflammation and microcirculatory damage in acute gastric lesions

Legal Events

Date	Code	Title	Description
2013-07-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application